ArticleInternational journal of clinical and experimental medicine2015
RASAL2 inhibited the proliferation and metastasis capability of nasopharyngeal carcinoma.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma.International journal of biological sciences · 2022Article
- RASAL2 suppresses the proliferative and invasive ability of PC3 prostate cancer cells.Oncotarget · 2021Article
- The Role of hsa-miR-21 and Its Target Genes Involved in Nasopharyngeal Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- PRKAA/AMPKα phosphorylation switches the role of RASAL2 from a suppressor to an activator of autophagy.Autophagy · 2021Article
- miR‑654‑3p suppresses cell viability and promotes apoptosis by targeting RASAL2 in non‑small‑cell lung cancer.Molecular medicine reports · 2021Article
- Suppressive effects of RASAL2 on renal cell carcinoma via SOX2/ERK/p38 MAPK pathway.Experimental and therapeutic medicine · 2020Article
- Pumping the brakes on RAS - negative regulators and death effectors of RAS.Journal of cell science · 2020Review
- Epigenetic changes in fibroblasts drive cancer metabolism and differentiation.Endocrine-related cancer · 2019Review
- Long noncoding RNA SMAD5-AS1 acts as a microRNA-106a-5p sponge to promote epithelial mesenchymal transition in nasopharyngeal carcinoma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- RASAL2 Plays Inconsistent Roles in Different Cancers.Frontiers in oncology · 2019Review
- The expression and function of RASAL2 in renal cell carcinoma angiogenesis.Cell death & disease · 2018Article
- RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer.Cell death & disease · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, RASAL2 has been found to function as a tumor and metastasis suppressor. RASAL2 inhibited tumor growth, progression, and metastasis in several cancers. However, the regulatory effect of RASAL2 in NPC still remains unclear. The purpose of this paper was to identify the role of RASAL2 in the metastasis of NPC. The expression of RASAL2 in human NPC was obviously down-regulated by real-time PCR analysis. Furthermore, knock-down of RASAL2 with siRNA treatment resulted in a promotion of cell proliferation and migration in vitro. Additionally, transwell analysis results revealed that the number of invasion cells was increased of cells treated with RASAL2 siRNA. We further explored the mechanism and demonstrated that the down-regulated RASAL2 promoted migration and invasion via EMT induction with E-cadherin decreased expression and vimentin, N-cadherin, and Snail increased expression in NPC cells.In conclusion, RASAL2 inhibited the proliferation and metastasis capability of NPC cells.
Indexed as
Identifiers
26770493PMC4694393W2410194577What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.